Investing Profile

Bali Muralidhar

InvestorVC
Managing Partner, Chief Investment Officer at Abingworth
Photo of Bali Muralidhar, Managing Partner at Abingworth

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
IT CRUX Mobile Apps Solutions Network
397 CONNECTIONS
IT CRUX Mobile Apps Solutions Network
397 CONNECTIONS
IT CRUX Mobile Apps Solutions Network
397 CONNECTIONS
University of Oxford Network
158 CONNECTIONS
Bain & Company Network
157 CONNECTIONS
cb
Abingworth Managing Partner
$15.0M - $30.0M
$22.5M
14
$465M
CompanyStageDateRound SizeTotal Raised
Cytospire Therapeutics
Series AMay 2026$83M
$83M
Wugen
Series CAug 2025$120M
Series BJul 2021$170M
$290M
Co-investors: John McKearn (RiverVest), Niall O’Donnell (RiverVest)
Glycomine
Series CApr 2025$120M
Series BJun 2021$35M
$150M
Co-investors: Niall O’Donnell (RiverVest)
AdvanCell
Series CFeb 2025$110M
$110M
Co-investors: Jamil Beg (5am Ventures)
Ascend Gene & Cell Therapies
Series AMar 2023$66M
$66M
Co-investors: Andrew Sinclair (Abingworth)
Anjarium Biosciences
Series ASep 2021$60M
$60M
CymaBay Therapeutics
Post Ipo DebtAug 2021$100M
$190M
Co-investors: Andrew Schwab (5am Ventures), Tony Evnin (Venrock)
Reneo Pharmaceuticals
Series BDec 2020$95M
$150M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Niall O’Donnell (RiverVest)
Global Head of Life Sciences AbingworthPresent
Non Executive Director British Business BankPresent
Managing Partner, Chief Investment Officer AbingworthPresent
Managing Partner AbingworthPresent
Partner AbingworthPresent
Partner MVM PartnersPresent
Associate Bain CapitalPresent
Consultant Bain & CompanyPresent
Bye-Fellow IT CRUX Mobile Apps SolutionsPresent
Researcher IT CRUX Mobile Apps SolutionsPresent
Clinical Fellow IT CRUX Mobile Apps SolutionsPresent
University of Cambridge MA Medical Science
University of Oxford BMBCh Clinical medicine
University of Cambridge PhD Cancer biology